期刊文献+

Maastricht Ⅱ treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori 被引量:23

Maastricht Ⅱ treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori
在线阅读 下载PDF
导出
摘要 AIM: The Maastricht Ⅱ criteria suggest the use of amoxicillin and clarithromycin in addition to a proton pump inhibitor over 7-10 d as a first line therapy in the eradication of Helicobacter pylori (Hpylori). For each proton pump inhibitor, various rates of eradication have been reported. The present study was to compare the efficacy of different proton pump inhibitors like omeprazole, lansoprazole and pantoprazole in combination with amoxicillin and clarithromycin in the first line eradication of Hpylonand to investigate the success of H pylonrieradication in our district. METHODS: A total of 139 patients were included having a Helicobacter pylori (+) gastroduodenal disorders diagnosed by means of histology and urease test. Besides amoxicillin (1000 mg twice a day) and darithromycin (500 mg twice a day), they were randomized to take omeprazole (20 mg twice a day), or lansoprazole (30 mg twice a day), or pantoprozole (40 mg twice a day) for 14 d. Four weeks after the therapy, the eradication was assessed by means of histology and urease test. It was evaluated as eradicated if the Hpyloriwas found negative in both. The complaints (pain in epigastrium, nocturnal pain, pyrosis and bloating) were graded in accordance with the Licert scale. The compliance of the patients was recorded. RESULTS: The eradication was found to be 40.8% in the omeprazole group, 43.5% in the lansoprazole group and 47.4% in the pantoprazole group. Sixty-three out of 139 patients (45%) had eradication. No statistically significant difference was observed between the groups. Significant improvements were seen in terms of the impact on the symptom scores in each group. CONCLUSION: There was no difference between omeprazole, lansoprazole and pantoprazole in H pylori eradication, and the rate of eradication was as low as 45%. Symptoms were improved independent of the eradication in each treatment group. The low eradication rates suggest that the antibiotic resistance or the genetic differences of the microorganism might be in effect. Further studies are required to verify these suggestions. AIM:The Maastricht Ⅱ criteria suggest the use of amoxicillin and darithromycin in addition to a proton pump inhibitor over 7-10 d as a first line therapy in the eradication of Helicobacter pylori(Hpylori).For each proton pump inhibitor,various rates of eradication have been reported.The present study was to compare the efficacy of different proton pump inhibitors like omeprazole,lansoprazole and pantoprazole in combination with amoxicillin and clarithromycin in the first line eradication of Hpy/onand to investigate the success of Hpyloneradication in our district. METHODS:A total of 139 patients were included having a Heelicobacter pylori(+) gastroduodenal disorders diagnosed by means of histology and urease test.Besides amoxicillin (1000mg twice a day) and clarithromycin (500mg twice a day),they were randomized to take omeprazole (20mg twice a day),or lansoprazole (30mg twice a day),or pantoprozole (40mg twice a day) for 14 d,Four weeks after the therapy,the eradication was assessed by means of histology and urease test.It was evaluated as eradicated if the H pylori was found negative in both.The complaints (pain in epigastrium,nocturnal pain,pyrosis and bloating) were graded in accordance with the Licert scale.The compliance of the patients was recorded. RESULTS:The eradication was found to be 40.8% in the omeprazole group,43.5% in the lansoprazole group and 47.4% in the pantoprazole group.Sixty-three out of 139 patients (45%) had eradication.No statistically significant difference was observed between the groups.Significant improvements were seen in terms of the impact on the symptom scores in each group. CONCLUSION:There was no difference between omeprazole,lansoprazole and pantoprazole in H pylori eradication,and the rate of eradication was as low as 45%. Symptoms were improved independent of the eradication in each treatment group.The low eradication rates suggest that the antibiotic resistance or the genetic differences of the microorganism might be in effect.Further studies are required to verify these suggestions.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第11期1656-1658,共3页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献31

  • 1Fennerty MB. What are the treatment goals for helicobacter pylori infection? Gastroenterology 1997; 113 (Suppl): S120-125.
  • 2Malfertheiner P, Megraud F, O;Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of helicobacter pylori infection-The Maastricht 2-2 000 Consensus report, Aliment Pharmacol Ther 2002; 16:167-180.
  • 3Herrerias JM, Bujanda L, Pena D. Efficacy and cost study in Portugal and Spain of three different 7 day eradication regimens of Helicobacter pylori. Gastroenterology 1999; 116:A186.
  • 4Spinzi GC, Bortoli A, Corbellini A. One Week therapy with omeprazole (PPY) or ranitidine bismuth citrate (RBC) and two antibiotics for the eradication of Helicobacter pylori in duodenal ulcer: a preliminary report. Gastroenterolgy 1998; 116:A294.
  • 5Sung JY, Leung WK, Ling TK, Yung MY, Chan FK, Lee YT, Cheng AF, Chung SC. One week use of ranitidine bismuth citrate,amoxicillin and claritromycin for the treatment of Helicobacter pylori related duodenal ulcer. Aliment Pharmacol Ther 1998; 12:723-730.
  • 6Susi D. The best treatment for Helicobacter pylori infection among for different 7 day triple therapies, Gut 1998; 43 (Suppl 2): A80.
  • 7Peura DA. The report of the digestive health initiative international update conference on Helicobacter pylori. Gastroenterology 1997; 113:4-8.
  • 8Chey WD. Treating Helicobacter pylori: candidate and regimen selection. Contemp 1997; 9:52-61.
  • 9Pounder RE. New developments in H pylori eradication therapy. Scand J Gastroenterol 1997; 32 (suppl): 43-45.
  • 10The European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8-13.

同被引文献112

引证文献23

二级引证文献184

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部